[Periarteritis nodosa related to hepatitis B virus. Determination of a new therapeutic strategy: 13 cases].
The treatment and prognosis of periarteritis nodosa associated with hepatitis B virus were reconsidered from a series of 13 patients representing 32.5 per cent of the 40 patients with periarteritis nodosa admitted during the same period. HBs and HBe antigens were present in every case, and hepatitis B virus replication was demonstrated by the finding of viral DNA in serum. One patient had anti-HBc IgM's. Five patients were treated with corticosteroids, cyclophosphamide and occasional plasma exchanges. All were cured or achieved complete remission. Eight patients were treated with plasma exchanges and vidarabine, either as first-line therapy (3 cases) or after failure of corticosteroids and/or immunosuppressants (5 cases). This treatment was clinically effective in 5/8 cases, including 3 with seroconversion. The 2 patients in whom the combined treatment failed were given corticosteroids; one of them also had plasma exchanges. The 8th patient died after a few days of treatment. Eleven of the 13 patients are still alive and either cured or in complete remission. Two patients who developed severe chronic hepatitis after steroids were discontinued received vidarabine alone: arrest of viral replication was obtained in both cases, with emergence of an anti-HBe (but not anti-HBs) antibody. The overall positive virological response rate to vidarabine alone or combined with plasma exchanges was 50 per cent. When vidarabine was prescribed as treatment of acute periarteritis nodosa (the 2 cases where it was used for chronic hepatitis being excluded), this response rate was 37.5 per cent. This, in patients with periarteritis nodosa associated with hepatitis B virus immunosuppressive drugs should be withdrawn and replaced by plasma exchanges and antiviral agents. This would be the first-line treatment to be replaced by corticosteroid therapy if it fails.
D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000150:complications* / Q000628:therapy; D006801:Humans; D010951:Plasma Exchange; D010488:Polyarteritis Nodosa / Q000209:etiology* / Q000628:therapy; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D014740:Vidarabine / Q000627:therapeutic use
D003520:Cyclophosphamide; D014740:Vidarabine; D011241:Prednisone
Périartérite noueuse liée au virus de l'hépatite B. Détermination d'une stratégie thérapeutique nouvelle: 13 observations.